

# Professor Frances L Game

---



## Current position

Consultant Diabetologist,  
Department of Diabetes and Endocrinology,  
Clinical Director R&D, Derby Hospitals NHS Foundation Trust.  
Honorary Professor, University of Nottingham

## Summary of qualifications

BSc (Hons) 1<sup>st</sup> class Biochemistry. University of Wales 1982  
MBBCh (Hons) Welsh National School of Medicine, University of Wales.  
1985  
MRCP (UK) 1988  
MRCPATH (Chemical Pathology) 1996  
CCST Diabetes Endocrinology and General Internal Medicine 1999  
FRCP 2004

## Previous Professional experience

Consultant Physician, Diabetes and Endocrinology  
Nottingham University Hospital  
Nottingham, UK  
April 2000- March 2011

## Grants

### **Nottingham and Derby R&D £46,615. 2003-2004**

Feasibility study for a prospective trial to evaluate education in the primary prevention of foot ulcers (Co-investigator)

### **Diabetes UK £73,182. 2003- 2006**

3 year evaluation of an education programme in the secondary prevention of foot ulcers (Co-investigator)

**Unconditional grant from Aventis/NovoNordisk/Roche. £12,000. 2004** to study effect of close glycaemic control on ulcer healing (Co-investigator)

### **Nottingham City Hospital R&D Pump-Priming Award £9,950.**

**2004-2005** Investigation of effect of haemodialysis on oxygenation of peripheral tissues (Chief Investigator)

**Diabetes UK £32,000. 2005-2007** A multicentre database for monitoring the Charcot foot in diabetes (Chief Investigator)

### **Biotec Pharmacon. £270,000. 2006-2009**

Multicentre trial to determine the efficacy and safety of soluble beta glucan in the management of diabetic foot ulcers (Co-Chief Investigator)

**NIHR (NEAT) £68,790. 2007-9** Evaluation of white light spectroscopy as a method of assessing distal limb blood flow (Co- Chief Investigator).

**NIHR (HTA) £1,358,852. 2011 – 2016** Evaluation of lightweight fibreglass heel cups in diabetic heel ulcers (Co- Chief Investigator)

**Reapplix ApS, Denmark. €2,000,000 2013-2017** Leucopatch 2. Leucopatch in the management of hard to heal diabetic foot ulcers: a multinational randomised controlled trial. (UK Chief Investigator)

**East Midlands Academic Health Science Network 2015**  
**£120,000** Making the Diabetic Foot Service more effective with innovative digital solution. Chief Investigator

**The Wellcome Trust £801,772. 2016-2019**  
“Assessing the efficacy of anti-staphylococcal phages in the management of infected foot ulcers in diabetes (Chief Investigator)

**NIHR (Programme Development Grant) £99,920 2016-2017**  
“Reducing the impact of diabetic foot ulcers on patients and the health service: the REDUCE programme” (Chief Instigator)

**East Midlands Academic Health Science Network £108,000, 2016**  
Making the Diabetic Foot Service more effective with innovative digital solution; the Silhouette project

## **Additional professional activities**

Chair Nottingham (2) Research Ethics Committee (Chair from May 2014, member from 2005)

Associate Editor Diabetic Medicine 2008- present

Co-Chair, East Midland Diabetic Foot Network 2012- present

Wound healing sub group of the International Working group of the Diabetic Foot, Secretary 2010-2011, Chair 2013-present.

Clinical Director Diabetes and Endocrinology, Derby Hospitals NHS FT November 2013 – September 2014.

Chair Drug and Therapeutics Committee Derby Hospitals NHS FT September 2012 – January 2014

Member of the American Diabetes Association task force of the definition and management of the Charcot foot in Diabetes 2011

Chair, Clinical Standards sub-group, Greater Nottingham Diabetes Network. 2008-2011.

Member Nottingham CTU steering Committee 2013-present

Member Trial Steering Committee, BASIL 3 Trial (NIHR) 2016-

Member Trial Steering Committee, OPTION-DM Study (NIHR) 2016-

## **Publications**

### **2016**

Jeffcoate WJ, Bus SA, **Game** FL, Hinchliffe RJ, Price PE, Schaper NC; International Working Group on the Diabetic Foot and the European Wound Management Association Reporting standards of studies and papers on the prevention and management of foot ulcers in **diabetes**: required details and markers of good quality. Lancet **Diabetes** Endocrinol. 2016 Sep;4(9):781-8. doi: 10.1016/S2213-8587(16)30012-

2. Epub 2016 May 10.

**Game FL**, Jeffcoate WJ. Dressings and Diabetic Foot Ulcers: A Current Review of the Evidence *Plast Reconstr Surg*. 2016 Sep;138(3 Suppl):158S-64S.

**Game F**. Classification of **diabetic foot** ulcers. *Diabetes Metab Res Rev*. 2016 Jan;32 Suppl 1:186-94.

**Game FL**, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, Price PE, Jeffcoate WJ; International Working Group on the **Diabetic Foot** (IWGDF). Effectiveness of interventions to enhance healing of chronic ulcers of the **foot** in diabetes: a systematic review. *Diabetes Metab Res Rev*. 2016 Jan;32 Suppl 1:154-68

**Game FL**, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, Price PE, Jeffcoate WJ. Effectiveness of interventions to enhance healing of chronic ulcers of the **foot** in diabetes: a systematic review. International Working Group on the **Diabetic Foot** (IWGDF). *Diabetes Metab Res Rev*. 2016 Jan;32 Suppl 1:154-68

## 2015

Jeffcoate WJ, Clark DJ, Savic N, Rodmell PI, Hinchliffe RJ, Musgrove A, **Game FL** Use of HSI to measure oxygen saturation in the lower limb and its correlation with healing of foot ulcers in diabetes. *Diabet Med*. 2015 Jun;32(6):798-802.

## 2014

Jeffcoate W, Game F, Price P, Phillips C, Turtle-Savage V Evaluation of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes: study protocol for a randomised controlled trial. *Trials*. 2014 Nov 26;15:462.

Fejfarová V, Jirkovská A, Dragomirecká E, **Game F**, Bém R, Dubský M, Wosková V, Křížová M, Skibová J, Wu S. Does the Diabetic Foot Have a Significant Impact on Selected Psychological or Social Characteristics of Patients with Diabetes Mellitus? *J Diabetes Res*. 2014 (epub)

**Game F**. Managing Diabetic Foot Disease In: *Diabetes Management in Clinical Practice* Tahseen Chowdary (ed). Springer 2014 (pp 93-110)

**Game F**. Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease. *Nephron Clin Pract*. 126(1):14-18.

Jeffcoate WJ, **Game FL**. Evidence for the Use of Biological Therapies in Ulcers of the Foot in Diabetes. *BioDrugs*. 2014 28(1):1-6

## 2013

**Game F** Obesity and the diabetic foot. *Diabetes in Practice*. 2013; 2 (3): 112–117

**Game FL**. Osteomyelitis in the diabetic foot: diagnosis and management. *Med Clin North Am*. 2013 Sep;97(5):947-56

Dumville JC, Hinchliffe RJ, Cullum N, **Game F**, Stubbs N, Sweeting M, Peinemann F. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. *Cochrane Database Syst Rev*. 2013 Oct 17;10

**Game F**, Jeffcoate W. The Charcot foot: neuropathic osteoarthropathy *Adv Skin Wound Care*. 2013 Sep;26(9): 421-8.

**Game FL**, Selby NM, McIntyre CW. Chronic kidney disease and the foot in diabetes - is inflammation the missing link? *Nephron Clin Pract*. 2013;123(1-2):36-40.

## 2012

**Game F**. Preventing amputations in patients with diabetes and renal disease. *Practical Diabetes* 2012 29(8),p 324-328

**Game F**. Diabetic foot disease in patients with renal disease. *J Renal Nursing* 2012 Vol.4; 5, 26 Sep 2012, pp 236 - 241

**Game F**. Management of diabetes around emergency and elective procedures. *Ann R Coll Surg Engl*. 2012;94(5):293-6

Bracewell N, **Game F**, Jeffcoate W, Scammell BE. Clinical evaluation of the VibraTip: a new device in the assessment of peripheral sensory neuropathy in diabetes. *Diabet Med*. 2012 Dec;29(12):1553-5

Rudrappa S, **Game F**, Jeffcoate W. Recurrence of the acute Charcot foot in diabetes. *Diabet Med*. 2012 Jun;29(6):819-21.

**Game F**. Update on drugs to treat diabetes *Ann R Coll Surg Engl*. 2012 May;94(4):221-3

**Game FL**, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Löndahl M, Price PE, Jeffcoate WJ. Specific guidelines on wound and wound-bed management. *Diabetes Metab Res Rev*. 2012 Feb;28 Suppl 1:232-3.

**Game FL**, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Löndahl M, Price PE, Jeffcoate WJ. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. *Diabetes Metab Res Rev*. 2012 Feb;28 Suppl 1:119-41

**Game F**. Choosing life or limb. Improving survival in the multi-complex diabetic foot patients. *Diabetes Metab Res Rev*. 2012 Feb;28 Suppl 1:97-100

**Game FL**, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, Jeffcoate WJ. Audit of acute Charcot's disease in UK: the CDUK study. *Diabetologia*. 2012 Jan;55(1):32-5

## 2011

Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, **Game F**, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L. The Charcot foot in diabetes *J Am Podiatr Med Assoc*. 2011;101(5):437-46

Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, **Game F**, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L. The Charcot foot in diabetes. *Diabetes Care*. 2011;34(9):2123-9.

McInnes A, Jeffcoate W, Vileikyte L, **Game F**, Lucas K, Higson N, Stuart L, Church A, Scanlan J, Anders J. Foot care education in patients with diabetes at low risk of complications: a consensus statement. *Diabet Med*. 2011 Feb;28(2):162-7

## 2010

**Game F**. Management of osteomyelitis of the foot in diabetes mellitus *Nat. Rev. Endocrinol*. 2010; 6, 43–47

Sharma A, Scammell BE, Fairbairn KJ, Seagrave MJ, **Game FL**, Jeffcoate WJ. Prevalence of calcification in the pedal arteries in diabetes complicated by foot disease. *Diabetes Care*. 2010 May;33(5):66

**Game F**. Diabetic Foot problems in End stage renal disease. *Int Diabetes Monitor* 2010; 22 (4), 138-143.

Van Baal J, **Game F**, Hubbard R, Jeffcoate WJ. Mortality associated with acute Charcot foot and neuropathic foot ulceration. *Diabetes Care* 2010; 33: 1086-1089

Jeffcoate WJ, Game FL New theories on the cause of the Charcot foot of diabetes. In: Frykberg R (ed) *The Charcot Foot and Ankle DTP*: Towson, Maryland pp29-43

## 2009

Jeffcoate WJ, Rasmussen LM, Hofbauer LC, **Game FL** Medial arterial calcification in diabetes and its relationship to neuropathy. *Diabetologia* 2009;52:2478-2488.

Jeffcoate WJ, Price PE, Phillips CJ, **Game FL**, Mudge E, Davies S, Amery CM, Edmonds ME, Gibby OM, Johnson AB, Jones GR, Masson E, Patmore JE, Price D, Rayman G, Harding KG Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in *diabetes Health Technology Assessment* 2009, vol./is. 13/54(1-86, iii-iv)

## 2008

Lincoln NB, Radford KA, **Game FL**, Jeffcoate WJ. Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. *Diabetologia*, November 2008, vol./is. 51/11(1954-61)

Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, **Game FL**, Hartemann-Heurtier A, Löndahl M, Price PE, van Houtum WH, Jeffcoate WJ Specific guidelines on wound and wound-bed management. *Diabetes/Metabolism Research Reviews*, 2008, vol./is. 24 Suppl 1/(S188-9), 1520-7552

Hinchliffe RJ, Valk GD, Apelqvist J, Armstrong DG, Bakker K, **Game FL**, Hartemann-Heurtier A, Löndahl M, Price PE, van Houtum WH, Jeffcoate WJ. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. *Diabetes/Metabolism Research Reviews*, 2008, vol./is. 24 Suppl 1/(S119-44), 1520-7552

**Game F**. The advantages and disadvantages of non-surgical management of the diabetic foot. *Diabetes/Metabolism Research Reviews*, 2008, vol./is. 24 Suppl 1/(S72-5), 1520-7552

**Game FL**, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. *Diabetologia*, June 2008, vol./is. 51/6 962-7.

Ince P, Abbas ZG, Lutale JK, Basit A, Ali SM, Chohan F, Morbach S, Mollenberg J, **Game FL**, Jeffcoate WJ. Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents. *Diabetes Care*, 2008, vol./is. 31/5(964-7), 1935-5548

Abbas ZG, Lutale JK, **Game FL**, Jeffcoate WJ. Comparison of four systems of classification of diabetic foot ulcers in Tanzania. *Diabetic Medicine*, 2008, vol./is. 25/2(134-7), 1464-5491

## 2007

Moustafa M, Bullock AJ, Creagh FM, Heller S, Jeffcoate W, **Game F**, Amery C, Tesfaye S, Ince Z, Haddow DB, MacNeil S. Randomized, controlled, single-blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers. *Regen-Med* 2007 2 (6) 887-902

Ince P, Kendrick D, **Game F**, Jeffcoate W. The association between baseline characteristics and the outcome of foot lesions in a UK population with diabetes. *Diabet Med* 2007 24, 977-81

Ince P, **Game FL**, Jeffcoate W. Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area. *Diabetes Care* 2007 30 (3) 660-3.

## 2006

Hinchliffe R J, Kirk B, Bhattacharjee D, Roe S, Jeffcoate W, **Game F**. The effect of haemodialysis on transcutaneous oxygen tension in patients with diabetes-a pilot study. *Nephrol-Dial-Transplant* 2006 21 (7) 1981-3.

Jeffcoate WJ, **Game FL**. Should annual measurement of the ankle-brachial index be routine practice in diabetes care? *Nat-Clin-Pract- Endocrinol-Metab* 2006 2 (10) 540-1

**Game FL**, Chipchase SY, Hubbard R, Burden RP, Jeffcoate WJ Temporal Association between the incidence of foot ulceration and the start of dialysis in diabetes mellitus. *Nephrol Dial Transplant* 2006 21 (11) 3207-10.

Jeffcoate WJ, Chipchase SY, **Game FL**. Assessing the outcome of diabetic foot ulcers using ulcer-related and person-related outcomes. *Diabetes Care* 2006 29 (8): 1784-7

Jeffcoate W, **Game F**. The description, classification and registration of diabetic foot lesions. In *The Foot in Diabetes* 4<sup>th</sup> edn (Boulton AJM, Cavanagh PR, Rayman G, eds). London: John Wiley & Sons Ltd.

Hinchliffe RJ, Jeffcoate WJ, **Game FL**. Diabetes, established renal failure and the risk to the lower limb. *Pract Diab Int* 23: 1-5.

## 2005

Idris I, **Game F**, Jeffcoate W. Does close glycaemic control promote healing in diabetic foot ulcers ? Report of a feasibility study. *Diabetic Medicine* 22(8): 1060-3

Pound N, Chipchase S, Treece K, **Game FL**, Jeffcoate W. Ulcer-free survival following management of foot ulcers in diabetes. *Diabetic Medicine* 10 (22): 1306-9.

Chipchase SY, Treece KA, Pound N, **Game FL**, Jeffcoate WJ. Heel ulcers don't heal in diabetes. Or do they? *Diabetic Medicine* 2(9) 1258-62

Jeffcoate WJ, **Game F**, Cavanagh P. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. *Lancet* 366 (9502) 2058-61.

Jeffcoate W, **Game F**, Hartemann-Heurtier A. Infection du pied diabétique. in *Journées de Diabétologie Hôtel-Dieu*. Paris: Médecine-Sciences, Flammarion, pp 131-41.

## 2004

Gazis A, Pound N, Macfarlane R, Treece K, **Game F**, Jeffcoate W. Morbidity and mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). *Diabetic Medicine* 21: 1243-1246.

Treece KA, Macfarlane RM, Pound N, **Game FL**, Jeffcoate WJ. Validation of a system of foot ulcer classification in diabetes mellitus. *Diabetic Medicine* 21: 987-991.

Jeffcoate WJ, Idris I, **Game FL**. Erythromelia or Mitchell's syndrome-new names for unexplained signs of inflammation in distal symmetrical neuropathy in diabetes *Diabetic Medicine* 21(12): 1334-8.

**Game F**, Jeffcoate WJ. MRSA and infection of the foot in diabetes. *Diabet Med* 21 (Suppl 4): 16-9

Jeffcoate W, **Game F**. Reducing the menace of gangrene and amputation in the diabetic foot. *Diabetographia Medical Review* 6: 5-7

## 2001

**Game FL**, Jones AF. Coronary heart disease risk assessment in diabetes mellitus – a comparison of PROCAM and Framingham functions. *Diabetic Medicine* 18:355-359.

**Game FL**, WA Bartlett, GR Bayly, AF Jones. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. *Diabetes, Obesity and Metabolism* 3(4): 279-86.

AF Jones, J Walker, C Jewkes, **FL Game**, WA Bartlett, T Marshall and GR Bayly Comparative accuracy of cardiovascular risk prediction methods in general practice patients. *Heart* 85 (1): 37 –43

**Game FL** and Jones AF. Ethnicity and risk factors for coronary heart disease in diabetes mellitus. *Diabetes, Obesity and Metabolism* 2: 91-97.

## 1999

Bayly GR, Bartlett WA, Davies PH, Husband D, Haddon A, **Game FL**, Jones AF. Laboratory-based calculation of coronary heart disease risk in a hospital diabetes clinic. *Diabetic Medicine* 16: 697-701.

AF Jones and **Game FL** Cardiovascular risk assessment  
*Modern Hypertension Management* 1(1) : 10-13.

MF Laker and **Game FL** Laboratory investigation of dyslipoproteinaemia. In Betteridge DJ, Illingworth DR and Sheperd J eds. *Lipoproteins in Health and Disease* Arnold, London.

### **1996**

**Game FL**. Adverse effects of drugs used to treat hyperlipidaemia.  
*Adverse Drug Reaction Bulletin* 109: 435-8.

**Game F**. Therapy and clinical trials [editorial]. *Current Opinion In Lipidology*. 7(3):U105-7.

### **1995**

Neary RH, Kilby MD, Kumputala P, Game FL, Bhatnagar D, Durrington PN and O'Brien PM. Fetal and maternal lipoprotein metabolism in human pregnancy. *Clinical Science* 88(3): 311-8.

### **1994**

Gregory WL, Game FL, Farrer M, Idle JR, Laker MF and James OF.  
Reduced serum lipoprotein (a) levels in patients with primary biliary cirrhosis.  
*Atherosclerosis* 105(1): 43-50.

### **1993**

Farrer M, **Game FL**, Albers CJ, Neil HA, Winocour PH, Laker MF, Adams PC and Alberti KG. Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.  
*BMJ* 307(6908): 832-6.

Stewart M, Laker MF, Dyer RG, **Game F**, Mitcheson J and Alberti KG.  
Lipoprotein compositional abnormalities and insulin resistance in Type II diabetic patients with mild hyperlipidaemia.  
*Arteriosclerosis and Thrombosis* 13(7):1046-52.

### **1992**

Farrer M, **Game FL**, Adams PC, Laker MF and Alberti KGMM.  
A simple, sensitive technique for classification of apolipoprotein(a) isoforms by sodium dodecyl sulphate polyacrylamide gel electrophoresis.  
*Clinica Chimica Acta* 207(3): 215-25.

### **1990**

Laker MF and **Game FL** Approaches to Lipid and Lipoprotein Analysis.  
In Bailliere's Clinical Endocrinology and Metabolism Volume 4/ Number 4

### **1988**

Hosker HSR, Lindsay DC, **Game F**, Codd AA, Dale G and Record COR.  
Incidence and types of acute viral hepatitis in Newcastle upon Tyne.  
*Postgraduate Medical Journal* 64: 854-855.

## **Selected Lectures- National and International**

### **2015**

Royal College of Physicians and Surgeons of Glasgow, Endocrinology and Diabetes training day:  
Difficult Problems and Hot Topics. *Why is my foot swollen?*

7<sup>th</sup> International Symposium on the Diabetic Foot. The Hague, Netherlands May 2015  
*Debridement and choice of wound dressing (workshop)*  
*Classification of diabetic foot ulcers*

Royal Society of Medicine diabetes training day. London July 2015 "*Classification of diabetic foot ulcers and Charcot neuroarthropathy*"

Aydin International Symposium on the Diabetic Foot Kusadasi, Turkey. October 2015  
*Medical or surgical management of Charcot foot: when and how*  
*New IWGDF wound healing guideline*

The Desert Foot meeting, Arizona, USA October 2015.  
*Paul Brand Lecture: Managing the High Risk Foot - Lessons from the UK*  
*The Diabetic Charcot Foot - Inflammation and Genes*

### **2014**

Diabetic Foot Global Conference, March 2014, Los Angeles USA, "*Game Theory: Odds and Ends about Endpoints and Odds*"

2014 International Course on Diabetic Foot April 2014 Florence, Italy *"Do we know when antibiotics are NOT recommended?"*

Georgetown University Hospital Annual Diabetic Limb Salvage Conference 2014, October 2014, Washington, USA *"The Team Concept: Essential Components to Success"*

### **2013**

Advanced podiatric practitioners of Australia High Risk Foot Group, November 2013, Melbourne, Australia. *'International cutting edge research activities in diabetes related foot ulcers and preventing amputation'*

7<sup>th</sup> National Conference for Intermediate Care Team, July 2013, London. *"Diabetic foot disease and the intermediate care team: Where do responsibilities begin and end?"*

11<sup>th</sup> Annual Conference Diabetic Foot Study Group of the EASD October 2013, Sitges, Spain *"Osteomyelitis in the ulcerated diabetic foot. How to treat primarily?"*

7<sup>th</sup> Annual meeting of the Association of Children's Diabetologists, February 2013, Warwick. *"Foot care and Diabetes"* (workshop)

### **2012**

8<sup>th</sup> National Conference of the Primary Care Diabetes Society, November 2012, Birmingham UK. *"Role of general practice in prevention and management of the diabetic foot"*

Annual Forum on Diabetic Foot and Related Diseases, Guangzhou, China October 2012 *"The management of osteomyelitis in diabetic foot disease", "How can we really improve the outcome of foot ulcers in diabetes ?" "Diabetologists' role in the management of diabetic foot disease"*

Annual Conference of the European Wound Management Association, Vienna, May 2012 *"Diabetic Foot Topical treatment/wound dressings"*

The first joint meeting of the Association of British Clinical Diabetologists and The Renal Association, Birmingham UK *"Preventing amputations in people with diabetes and kidney disease"*

The 14<sup>th</sup> Malvern International Diabetic Foot Conference May 2012, Malvern UK *"Osteomyelitis- medical or surgical management"*

The Renal Association conference 2012, Manchester UK *"Diabetes and foot disease in patients with renal disease"*

22<sup>nd</sup> Conference of the European Wound Management Association May 2012, Vienna, Austria *"Diabetic Foot: Topical treatment and wound dressings"*

Annual Diabetic Foot conference, Slovenia. May 2012 Villa Bled, Slovenia *"Infection or Charcot"*

### **2011**

Diabetic Foot Global Conference 2011 Los Angeles, USA *"The Best Kept Secrets on Her Majesty's Foot Service"*

6<sup>th</sup> International Symposium on the Diabetic Foot, Noordwijkerhout, Netherlands *"Choosing for life or leg? Improving long-term survival of the multicomplexed diabetic foot patient"*

International Diabetic Limb Salvage Conference, Washington DC *"Defining the Dysfunctional Limb: Can and Should One Live with It?"*

International Diabetic Limb Salvage Conference, Washington DC *"The Curse of Neuropathy: How Can the Patient Adjust to Control Pain and Diminish Risk for Ulceration?"*

### **2010**

Young Diabetologists Forum (DUK) *"The Diabetic Foot- a practical guide"*

### **2009**

The 10<sup>th</sup> national conference - The Diabetes Epidemic (BJHM), London UK *"Management of diabetic foot ulcers"*

Diabetes UK Annual Professional Conference, Glasgow UK  
*"The medical vs Surgical management of osteomyelitis"*

**2008**

12th International Malvern Diabetic Foot Conference Great Malvern UK  
*"Non-surgical management of osteomyelitis"*

**2007**

Diabetes UK Annual Professional Conference, Glasgow UK  
*"The Charcot Foot-CDUK one year on"*

5th International Symposium on the Diabetic Foot, Noordwijkerhout, Netherlands  
*"The advantages and disadvantages of non-surgical management of the diabetic foot"*

National Conference of the Dutch Orthopaedic Society, Eindhoven, Netherlands  
*"The Diabetic Foot"*

**2006**

Belfast Wound care Research group, Belfast, N Ireland.  
*"The Charcot Foot Register – benefits & limitations"*

**Guideline Committees- National and International**

Joint British Diabetes Societies Guidelines development group; Diabetes in the Dialysis Unit 2014 –

International working group of the Diabetic Foot – wound healing subgroup 2007 and 2011 (secretary),  
2013 (Chair)

American Diabetes Association- American Podiatric Medical Association Joint Task Force on Charcot  
Foot 2011

National Diabetes Reference Dataset (NDRD) Development – Diabetic Foot Group 2010